News
PBM
2.970
+9.59%
0.260
Weekly Report: what happened at PBM last week (0615-0619)?
Weekly Report · 5d ago
Weekly Report: what happened at PBM last week (0608-0612)?
Weekly Report · 06/15 10:30
Weekly Report: what happened at PBM last week (0601-0605)?
Weekly Report · 06/08 10:25
Psyence Biomedical Corrects Technical Error in 2023 Equity Incentive Plan
TipRanks · 06/05 21:26
Launch One Acquisition names Daniel Clifford Rogers audit committee chair after Stack resignation
PUBT · 06/02 21:16
Weekly Report: what happened at PBM last week (0525-0529)?
Weekly Report · 06/01 10:31
Weekly Report: what happened at PBM last week (0518-0522)?
Weekly Report · 05/25 10:34
12 Health Care Stocks Moving In Tuesday's Intraday Session
Benzinga · 05/19 17:06
Weekly Report: what happened at PBM last week (0511-0515)?
Weekly Report · 05/18 10:34
Psyence BioMed targets U.S. push for GMP ibogaine research, manufacturing
PUBT · 05/16 05:17
Psyence Biomedical announces U.S. engagement initiative focused on ibogaine
TipRanks · 05/15 14:51
Psyence BioMed Establishes Active Ibogaine Operations, Production Capabilities In Africa
Benzinga · 05/15 13:18
PSYENCE BIOMED ANNOUNCES U.S. STRATEGIC ENGAGEMENT INITIATIVE FOCUSED ON GMP IBOGAINE RESEARCH AND MANUFACTURING
Reuters · 05/15 13:15
12 Health Care Stocks Moving In Wednesday's After-Market Session
Benzinga · 05/13 21:06
Prestige Consumer Healthcare Announces agreement To Acquire LaCorium Health, A Leader In Australian Therapeutic Skin Care For ~150M
Benzinga · 05/13 20:33
Weekly Report: what happened at PBM last week (0504-0508)?
Weekly Report · 05/11 10:31
Weekly Report: what happened at PBM last week (0427-0501)?
Weekly Report · 05/04 10:28
12 Health Care Stocks Moving In Friday's Pre-Market Session
Benzinga · 05/01 12:05
Weekly Report: what happened at PBM last week (0420-0424)?
Weekly Report · 04/27 10:31
Psyence BioMed begins Phase IIb dosing of NPX-5 in adjustment disorder trial
PUBT · 04/24 06:37
More
Webull provides a variety of real-time PBM stock news. You can receive the latest news about Psyence Biomedical Ltd. through multiple platforms. This information may help you make smarter investment decisions.
About PBM
Psyence Biomedical Ltd is a multi-asset, vertically integrated biopharmaceutical company specializing in psychedelic-based therapeutics. The Company is focused on developing nature-derived (non-synthetic) psilocybin-based psychedelic medicine. It is dedicated to addressing unmet mental health needs, particularly in palliative care. Its ongoing Phase IIb psilocybin clinical trial in Australia focuses on adjustment disorder in patients diagnosed with cancer.